IDO1 and melanoma: However, the key clinical trial on melanoma patients in Phase III using epacadostat (an IDO1 inhibitor) in combination with pembrolizumab (PD1 inhibitor) drugs, did not improve overall survival compared to placebo plus pembrolizumab [74].